Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Novo Nordisk’s once-weekly IcoSema shows promise in phase 3a type 2 diabetes trial

IcoSema showed non-inferiority to daily insulin treatment in reducing blood glucose levels

- PMLiVE

AstraZeneca/Sanofi’s RSV treatment shown to reduce hospitalisations in infants

Beyfortus showed an over 80% reduction in hospitalisations associated with the virus

- PMLiVE

FDA authorises Florida’s request to import cheaper prescription drugs from Canada

The first-of-its-kind importation programme is expected to save the state up to $180m in its first year

- PMLiVE

Evoke unveils simplified brand and structure: Inizio Evoke

The new brand will deliver more connected solutions for clients to address the demands of the dynamic global healthcare marketplace

- PMLiVE

Continuously capable – how firms stay ahead of their rivals using ‘acme comparators’

Helping firms identify not just the direction of their capability development but also the ways to achieve it

EU flag

EC approves UCB’s Rystiggo to treat generalised myasthenia gravis

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

- PMLiVE

New antibiotic compound could potentially treat lethal hospital infections

Zosurabalpin successfully eliminated the multi-resistant A baumannii bacteria

- PMLiVE

Boehringer Ingelheim and 3T announce second cancer immunotherapy partnership

The collaboration brings the potential milestone payments of the agreements to $538.5m

- PMLiVE

Study suggests hearing aids could prevent onset and progression of dementia

People with severe hearing loss had an increased risk of up to 20% of developing dementia

- PMLiVE

Novartis shares positive phase 3 results for Scemblix in chronic myeloid leukaemia

More than 6,300 people are diagnosed with the disease every year in Europe

- PMLiVE

Living in a VUCA world

It’s been a year characterised by volatility, uncertainty, complexity and ambiguity

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...

Impetus Digital

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links